title: Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer.
abstract: BACKGROUND
  We evaluated the efficacy and feasibility of hyperthermic intraperitoneal chemotherapy (HIPEC) using paclitaxel as consolidation therapy in patients with epithelial ovarian cancer.
  
  
  METHODS
  Between November 1999 and January 2004, 18 patients with a negative second-look and 1 patient with positive peritoneal cytology only with stage Ic-IIIc epithelial ovarian cancer received consolidation intra-operative HIPEC using paclitaxel. The HIPEC was performed with open-abdomen technique, using 6 L of lactated Ringer's solution containing paclitaxel 175 mg/m(2), for 90 min in hyperthermic phase (43-44 degrees C). The survival rates were compared with 24 patients treated with conventional therapy (control group).
  
  
  RESULTS
  The 8-year progression-free survival rates were 63.16% in the HIPEC-paclitaxel group and 29.17% in the control group (P = 0.027). The 8-year overall survival rates were 84.21% in the HIPEC-paclitaxel group and 25.00% in the control group (P = 0.0004). The time interval between initial treatment and HIPEC was statistically significant with respect to progression-free and overall survival in the HIPEC-paclitaxel group.
  
  
  CONCLUSIONS
  HIPEC with paclitaxel during 2nd-look laparotomy is feasible and relatively safe and showed a good effect on survival. In patients with epithelial ovarian cancer who have a complete pathologic response, HIPEC with paclitaxel should be considered as a consolidation treatment option.
authors.affiliation: Department of Obstetrics and Gynecology, Seoul Saint Mary's Hospital, The Catholic University of Korea, Seoul 137-040, South Korea.
authors.forename: Jin Hwi
authors.initials: JH
authors.lastname: Kim
authors.forename: Joon Mo
authors.initials: JM
authors.lastname: Lee
authors.forename: Ki Sung
authors.initials: KS
authors.lastname: Ryu
authors.forename: Yong Seok
authors.initials: YS
authors.lastname: Lee
authors.forename: Yong Gyu
authors.initials: YG
authors.lastname: Park
authors.forename: Soo Young
authors.initials: SY
authors.lastname: Hur
authors.forename: Keun Ho
authors.initials: KH
authors.lastname: Lee
authors.forename: Sung Ha
authors.initials: SH
authors.lastname: Lee
authors.forename: Seung Jo
authors.initials: SJ
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D007263:Infusions, Parenteral; D008875:Middle Aged; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel